A New Study Is Causing Doctors To Raise The Alarm On Common Alzheimer's Tests
But there's a catch: New research suggests that those blood tests may be unreliable, especially in Black patients. Doctors ...
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Breakthrough Drug Cuts Alzheimer’s Risk by 50% in High-Risk Patients
A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...
Neurology Advisor3d
Alzheimer Disease in People With Cancer: What’s the Risk?
Compared with same-aged adults who are cancer-free, older adults with cancer have a lower risk of developing Alzheimer disease and related dementias.
Technology Networks6d
Discontinued Alzheimer’s Drug Shows Potential for Disease Prevention in High-Risk Groups
A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...
Daily Express US on MSN12h
Doctor raves over simple food-and-drink combo that can slash dementia risk
Dr Megan Rossi, an award-winning scientist, has revealed a surprising food and drink combination that can significantly ...
The St. Louis American6d
A Link to better family health, Family Wellness Day fights disparities
More African American families should be linked into health care awareness, which includes screenings for diseases that ...
Doctor says simple diet swap can cut dementia risk
Dr Megan Rossi cited two breakthrough studies which suggested ways to reduce your risk of age-related cognitive decline ...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...
Cassava Sciences, Inc.: Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...